Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ia/Ib/II study of QLS2319 in healthy participants and cancer cachexia patients
CTR20263235Phase 2Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of QLS2319 in cancer anorexia-cachexia syndrome (CACS), sponsored by Qilu Pharmaceutical. Started Sep 2026; status: active.
02
Drugs
QLS2319
03
Conditions
cancer anorexia-cachexia syndrome (CACS)
Beyond the preview
Go deeper on CTR20263235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263235.